Psychedelic drug developers rally as Trump orders FDA to expedite reviews - Reuters
Psychedelic drug developers rally as Trump orders FDA to expedite reviews Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Notable Quotes
"the order is an 'official stamp of validation to the class,' showing that government support is real."
— Andrew Tsai , Executive
"is a substantial step towards diminishing regulatory risk for psychedelic drugs."
— Brian Abrahams , Executive
"In many cases, these experimental treatments have shown life changing potential for those suffering from severe mental illness and depression, including our cherished veterans, our veterans are having a tremendous hard time."
— Donald Trump , Politician
"I got a call from a number of people, including the great Joe Rogan, and he said, we have to do something about this."
— Donald Trump , Politician
Key People
Andrew Tsai is an analyst at Jefferies.
Brian Abrahams is an analyst at RBC.
Former president of the United States known for his aggressive economic policies.
Dr. Mehmet Oz is a television personality and former Republican candidate.
Joe Rogan is a popular podcast host known for discussing a wide range of topics, including politics.
Marty Makary is the FDA commissioner who announced Prasad's departure.
Robert F. Kennedy Jr. is an American environmental attorney and activist.
Robert F. Kennedy, Jr. is the Health and Human Services Secretary.
Tags
All Coverage
<a href="https://news.google.com/rss/articles/CBMi0AFBVV95cUxPRkt5UW9leHZFZmU0NUdRWWNIR3YtM19sNlZQRXduUFFmZWs2NXVXaGdYOTVTelNWQzRkbWU0cHhPU0hFYmw3VlN4VkhnTTJYMUVtZW95U1JvNHk4dUVfWjQ1X0s4XzRwV1JMS2dGZVFFcjZTYXhaelJhZGQ3RkZOLWNqSzdKMFJHcmFSZkNjTTFaVW9hWVZJMkZGM1lUVkxXQWRSRk1DYUU3LWZCdjFtcUh0dTVMM2lYUzE2SzVaSktFaTNtWExJX2cxODc0ZUFp?oc=5" target="_blank">Psychedelic drug developers rally as Trump orders FDA to expedite reviews</a> <font color="#6f6f6f">Reuters</font>
Shares of psychedelic drug developers rose after President Trump signed an executive order directing the FDA to fast-track reviews of psychedelic drugs and boost federal research funding.
President Trump signed an executive order to speed up access to medical research and treatment based on psychedelic drugs, instructing the FDA to expedite the review of drugs like ibogaine.
Shares of psychedelic drug developers rose after President Trump signed an executive order directing the FDA to fast-track reviews of psychedelic drugs and increase federal research funding.
President Trump signed an executive order to accelerate research and approval of psychedelic-based therapies, particularly ibogaine, for conditions like PTSD, depression, and addiction.
Similar Stories
Related coverage based on topic and tags
FDA seeks scientists and consumer representatives for advisory panels - reuters.com
FDA seeks scientists and consumer representatives for advisory panels reuters.com
September 30, 2026 at 08:30 PMUS FDA approves AbbVie's drug for Parkinson's disease - reuters.com
US FDA approves AbbVie's drug for Parkinson's disease reuters.com
September 25, 2026 at 10:57 PMTrump government ads draw scrutiny weeks before midterm elections - Reuters
Trump government ads draw scrutiny weeks before midterm elections Reuters
September 28, 2026 at 10:42 PMTrump moves swiftly to fill seat on conservative-packed US appeals court - reuters.com
Trump moves swiftly to fill seat on conservative-packed US appeals court reuters.com
October 1, 2026 at 08:51 PMUS FDA extends review of Novo Nordisk's hemophilia drug over facility issues - Reuters
US FDA extends review of Novo Nordisk's hemophilia drug over facility issues Reuters
October 2, 2026 at 09:52 PMTrump releases AI accord with tech executives - reuters.com
Trump releases AI accord with tech executives reuters.com
September 29, 2026 at 10:34 PM